Spectral, DFT/B3LYP and molecular docking analyses on ethyl 2-(5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7-yl)pent-4-enoate


SERT Y., Lahmidi S., El Hafi M., GÖKCE H., Essassi E. M., Ejjoumamany A., ...More

JOURNAL OF MOLECULAR STRUCTURE, vol.1206, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 1206
  • Publication Date: 2020
  • Doi Number: 10.1016/j.molstruc.2020.127680
  • Journal Name: JOURNAL OF MOLECULAR STRUCTURE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chimica, Compendex, INSPEC
  • Keywords: 1,2,4-triazolo[1,5-a]pyrimidine, Hirshfeld surface analysis, Spectral analysis, Molecular docking study, FT-RAMAN, SPECTROSCOPIC CHARACTERIZATION, 1ST-ORDER HYPERPOLARIZABILITY, NMR, IR, BINDING, POTENT, DFT
  • Yozgat Bozok University Affiliated: Yes

Abstract

In this paper, the compound ethyl 2-(5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7-yl)pent-4-enoate was synthesized and identified by FT-IR, H-1 and C-13 NMR, UV-Vis. And single crystal x-ray diffraction. In addition, theoretical calculations including an optimized structure analysis, Hirshfeld surface analysis, High Occupied Molecular Orbital (HOMO)-Lowest Unoccupied Molecular Orbital (LUMO) analysis, UV -Vis. parameters with an IEFPCM solvent model, MEP-Molecular Electrostatic Potential and NLO-NonLinear Optical properties and a molecular docking analysis were carried out. All theoretical computations were performed by the DET/B3LYP functional and the 6-311++G(d,p) basis set in the ground state. The assignments of calculated infrared vibrational frequencies were performed using the VEDA4 software for the first time through the optimized structure's chk*. and the experimental and theoretical data are in good agreement. In addition, molecular docking studies between ethyl 2-(5-methyl-1,2,4-triazolo [1,5-a]pyrimidin-7-yl)pent-4-enoateand the c-MET protein (PDB ID: 5EOB) were performed by using the AutoDock Vina program. The title molecule appears to be a good inhibitor for cancer treatment due to its binding energy and ability to adhere to the active sites of the protein. (C) 2020 Elsevier B.V. All rights reserved.